Movahed Afsaneh Yazdani, Bagheri Rana, Savatier Pierre, Šarić Tomo, Moradi Sharif
Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
University Lyon, University Lyon 1, INSERM, Stem Cell and Brain Research Institute U1208, 69500 Bron, France.
Stem Cell Reports. 2025 Jul 8;20(7):102543. doi: 10.1016/j.stemcr.2025.102543. Epub 2025 Jun 19.
Human pluripotent stem cells (hPSCs) are considered a promising tool for regenerative medicine due to their unique self-renewal and multi-lineage differentiation capabilities. Although over 100 clinical trials have employed hPSC-derived products to treat life-threatening diseases, the tumorigenic risk posed by residual undifferentiated hPSCs remains a formidable obstacle to their clinical implementation. In this review, we summarize current strategies to eliminate tumorigenic hPSCs, most of which target hPSC-specific markers, and critically evaluate the advantages and limitations of each approach. Finally, we discuss various methods that can be used to evaluate the efficiency of pluripotent stem cell (PSC) elimination.
人类多能干细胞(hPSCs)因其独特的自我更新和多谱系分化能力,被视为再生医学中一种很有前景的工具。尽管已有100多项临床试验使用hPSC衍生产品来治疗危及生命的疾病,但残留未分化hPSCs带来的致瘤风险仍然是其临床应用的巨大障碍。在本综述中,我们总结了当前消除致瘤性hPSCs的策略,其中大多数针对hPSC特异性标志物,并批判性地评估了每种方法的优缺点。最后,我们讨论了可用于评估多能干细胞(PSC)消除效率的各种方法。
Arch Ital Urol Androl. 2025-6-30
2025-1
Transl Neurodegener. 2024-10-29